ARTICLE SUMMARY:
By developing molecular diagnostics that effectively address very specific, relevant problems while saving the system money, Veracyte may be approaching a white-hot but economically challenging area of medical innovation with a viable value proposition. So far, it is winning the reimbursement wars, but now must scale its accomplishments into a sustainable business.
Veracyte Inc. was founded in 2008 as a spin-out of a biotech incubator formed by TPG Biotech, Kleiner Perkins, and Versant Ventures, all early supporters of the pioneering success of Genomic Health Inc.
